Health Trials

C3G

3

Review clinical trials related to C3G. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.

Participants needed: 98
Trial details
Phase: Phase 3Age: 12-60Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Jul 13, 2026Locations: 87
Eligibility criteria

Male and female participants age ≥ 12 and ≤ 60 years at screening. [+7]

Participants who have received any cell or organ transplantation, including a ki... [+9]

Read more
Status: Recruiting

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.

Participants needed: 45
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: ADARx Pharmaceuticals, Inc.Updated: Jun 16, 2026Locations: 29
Eligibility criteria

Mean eGFR greater than or equal to 30 mL/min/1.73m2 [+4]

Hereditary or acquired complement deficiency [+7]

Read more
Status: Recruiting

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.

Participants needed: 98
Trial details
Phase: Phase 3Age: 12-60Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Jun 1, 2026Locations: 87
Eligibility criteria

Male and female participants age ≥ 12 and ≤ 60 years at screening. [+7]

Participants who have received any cell or organ transplantation, including a ki... [+9]

Read more